What’s Next For ChemoCentryx Stock After Over A 100% Rise In A Month?

What’s Next For ChemoCentryx Stock After Over A 100% Rise In A Month?

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has skyrocketed with a 104% rise over the last month. This can be attributed to an unexpected U.S. FDA approval of Tavneos – an oral drug